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ABSTRACT
Purpose Neuropathic pain is a common disorder of 
the somatosensory system that affects 7%–10% of the 
general population. The disorder places a large social 
and economic burden on patients as well as healthcare 
services. However, not everyone with a relevant underlying 
aetiology develops corresponding pain. DOLORisk Dundee, 
a European Union- funded cohort, part of the multicentre 
DOLORisk consortium, was set up to increase current 
understanding of this variation in onset. In particular, the 
cohort will allow exploration of psychosocial, clinical and 
genetic predictors of neuropathic pain onset.
Participants DOLORisk Dundee has been constructed 
by rephenotyping two pre- existing Scottish population 
cohorts for neuropathic pain using a standardised 
‘core’ study protocol: Genetics of Diabetes Audit and 
Research in Tayside Scotland (GoDARTS) (n=5236) 
consisting of predominantly type 2 diabetics from the 
Tayside region, and Generation Scotland: Scottish Family 
Health Study (GS:SFHS; n=20 221). Rephenotyping was 
conducted in two phases: a baseline postal survey and a 
combined postal and online follow- up survey. DOLORisk 
Dundee consists of 9155 participants (GoDARTS=1915; 
GS:SFHS=7240) who responded to the baseline survey, 
of which 6338 (69.2%; GoDARTS=1046; GS:SFHS=5292) 
also responded to the follow- up survey (18 months later).
Findings to date At baseline, the proportion of those 
with chronic neuropathic pain (Douleur Neuropathique 
en 4 Questions questionnaire score ≥3, duration ≥3 
months) was 30.5% in GoDARTS and 14.2% in Generation 
Scotland. Electronic record linkage enables large scale 
genetic association studies to be conducted and risk 
models have been constructed for neuropathic pain.
Future plans The cohort is being maintained by an 
access committee, through which collaborations are 
encouraged. Details of how to do this will be available on 
the study website (http:// dolorisk. eu/). Further follow- up 
surveys of the cohort are planned and funding applications 
are being prepared to this effect. This will be conducted in 
harmony with similar pain rephenotyping of UK Biobank.
INTRODUCTION
Chronic pain, usually defined as pain lasting 
more than 3 months, can be either noci-
ceptive or neuropathic (though these may 
overlap). Neuropathic Pain (NP) is defined 
as ‘pain that arises as a direct consequence 
of a lesion or disease affecting the somato-
sensory system’1 and affects approximately 
20% of people with chronic pain.2 NP affects 
7%–10% of the general population3 and is 
associated with a set of unpleasant character-
istics including burning, pins and needles and 
electric shock- like sensations. The disorder is 
associated with poor quality of life, with 17% 
of people with NP rating their experience 
as being ‘worse than death’.2 It also places 
a large economic burden on patients and 
healthcare services with reduced productivity 
and employability at work and increased use 
of primary care with increasing pain severity.4 
Predictably, NP is associated with greater 
anxiety, depression5 and sleep disturbance6 
when compared with non- NP. Unfortunately, 
many common analgesics used to treat noci-
ceptive pain, including opioids, are generally 
Strengths and limitations of this study
 ► DOLORisk Dundee is unique in enabling longitudinal 
population studies of neuropathic pain and related 
chronic pain traits.
 ► It is the largest longitudinal cohort of neuropathic 
pain to date providing increased power to conduct 
epidemiological and genetic analyses.
 ► Use of a ‘core’ study protocol allows easy collab-
oration and comparison with other cohorts within 
the consortium as well as external cohorts such as 
UK Biobank, which is rephenotyping for neuropathic 
pain using a similar protocol.
 ► Dundee has created a bespoke database in which all 
participant data created within the DOLORisk con-
sortium is held and is available subject to access 
committee approval.
 ► DOLORisk Dundee has common limitations asso-
ciated with epidemiological studies, including loss 
to follow- up, and there was incomplete response to 
questions on aetiology and location of worst pain.
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ineffective in NP.7 Also, first- line medications used to treat 
NP, including gabapentin, pregabalin, duloxetine and 
amitriptyline, achieve satisfactory pain relief in less than 
half of people treated.7
Examples of disorders underlying NP are diabetes 
mellitus (causing painful diabetic neuropathy), herpes 
zoster (causing postherpetic neuralgia) and multiple 
sclerosis (which can be associated with trigeminal 
neuralgia). Contributing physical traumas to the 
nervous system include spinal cord injury, surgical 
procedures and amputation (resulting in phantom limb 
pain). However, not everyone with the same underlying 
disease or lesion develops NP. This is well demonstrated 
in diabetic polyneuropathy where only 20%–30% of 
people develop pain.3 The variation in onset and severity 
of NP is likely to be due to a combination of genetic, 
psychosocial, demographic and clinical factors. A recent 
twins study in the UK has estimated that genetic factors 
account for 37% of the variance in NP onset.8 However, 
the precise identity, magnitude and interaction of these 
factors have been poorly characterised, with previous 
analyses suffering from the usual limitations associated 
with epidemiology studies, including small sample size, 
cross- sectional design and heterogeneity in case defi-
nition.9 10 Nevertheless, detecting risk factors has the 
potential to improve prognosis and use of healthcare 
resources.
DOLORisk was set up in 2015 to understand the risk 
factors and determinants for NP.11 Funded by the Euro-
pean Commission’s Horizon 2020 programme, DOLORisk 
is a multicentre study with collaborators from 9 European 
countries assembling specific clinical cohorts to explore 
a common set of factors. The largest of these, DOLORisk 
Dundee, is based on two pre- existing population- based 
cohorts, and combines new phenotypic data, collected 
18 months apart, with genomic data. This study addresses 
some of the shortcomings identified in previous studies,12 
and focusses on the development of a risk model for NP 
onset and progression. The data will be available to other 
researchers to addressrelated questions.
COHORT DESCRIPTION
Participant sources
The recruitment flow for DOLORisk Dundee is provided 
in figure 1. The study makes use of two pre- existing 
Scottish genetic epidemiology cohorts; the Genetics 
of Diabetes Audit and Research in Tayside Scotland 
(GoDARTS) study13 and Generation Scotland: The Scot-
tish Family Health Study (GS:SFHS).14 GoDARTS consists 
of 18 306 participants drawn from the Tayside region of 
Scotland between 1998 and 2015 and 10,149 of which 
were recruited on the basis of their diagnosis of diabetes 
mellitus (most of which are type 2). The rest of the 
cohort was recruited as diabetes- free controls. GS:SFHS 
is a family- based cohort consisting of 24 084 participants 
recruited via general practices across Scotland from 2006 
to 2011. Demographic and lifestyle data were obtained 
in both cohorts via questionnaires, whereas basic health 
data was collected from clinical examinations. Partici-
pants also provided blood, urine or saliva samples for 
biochemical and whole- genome analysis. At the point 
of recruitment, participants provided informed consent 
for their baseline data to be linked pseudonymously to 
longitudinal National Health Service (NHS) medical 
records (including laboratory, prescribing, morbidity, 
hospital admissions and mortality data), and for these to 
be used in medical research. Furthermore, participants 
provided consent to being contacted again for future 
studies. Cohort profiles of both GoDARTS and GS:SFHS 
have been published, where more details of the recruit-
ment process and statistics for the individual studies can 
be found.13 14
Baseline survey
The eligibility criteria for the study are given in table 1. 
GS:SFHS collected information on the presence, site and 
severity of chronic pain, using validated questionnaires,11 
but did not screen for the presence of NP. As neither 
cohort held specific data on NP prior to the DOLORisk 
Dundee study, diabetic participants of GoDARTS 
(n=5236) and all participants of GS:SFHS (n=20 221), 
Figure 1 Recruitment flow for DOLORisk Dundee. GoDARTS, Genetics of Diabetes Audit and Research in Tayside Scotland; 
GS- SFHS, Generation Scotland: Scottish Family Health Study.
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who were consented, alive and resident in Scotland 
according to their NHS medical records, were contacted 
by post between May and December 2016 (figure 1). 
Each participant was invited to complete and return, by 
way of a prepaid envelope, a questionnaire on NP and 
other pain- related items (see below). Mailing packs also 
included the DOLORisk Dundee patient information 
leaflet (PIL) and invitation letter. Non- respondents were 
sent a reminder letter between November 2016 and April 
2017, which also included a copy of the study PIL. The 
baseline survey was closed to respondents in September 
2017. A total of 1915 people participated from GoDARTS 
by returning a completed questionnaire, a participation 
rate of 36.6% (1915/5236) and 7240 people returned a 
completed questionnaire from GS:SFHS, a participation 
rate of 35.8% (7240/20 221). As part of the question-
naire, consent was obtained for further contact regarding 
a follow- up survey on NP and participants were invited to 
provide an email address for this purpose. The consent 
rate was 84.6% (1620/1915) in GoDARTS and 95.7% in 
GS:SFHS (6929/7240).
Sociodemographic statistics comparing participants and 
non- participants of DOLORisk Dundee from GoDARTS 
and GS:SFHS are presented in table 2. In GoDARTS 
participants were younger (71 years vs 73 years, p<0.01), 
had a higher proportion of males (61% vs 53%, p<0.01) 
and were from less socioeconomically deprived areas 
(living in most affluent category of the Scottish Index of 
Multiple Deprivation (SIMD) Quintile 1: 16% vs 23%, 
p<0.01) than non- participants, while ethnicity was similar 
Table 1 Eligibility criteria for participation in DOLORisk Dundee
Phase Inclusion criteria Exclusion criteria
Baseline 1. Participants of Generation Scotland or GoDARTS 1. Participants of GoDARTS who are 
‘controls’ (diabetes free)
2. Provided consent to be recontacted about future studies as part 
of GoDARTS or GS:SFHS
  
3. Living at the time of the DOLORisk study according to NHS 
medical records
  
4. Resident in Scotland at the time of the DOLORisk study   
Follow- up 1. Participated in the baseline survey 1. Participants who had withdrawn 
from the study between baseline and 
follow- up
2. Provided additional consent to be recontacted about the follow- 
up survey
2. Participants who had died between 
baseline and follow- up
  3. Participants who were no longer 
living in Scotland
GoDARTS, Genetics of Diabetes Audit and Research in Tayside Scotland; GS:SFHS, Generation Scotland: Scottish Family Health Study; 
NHS, National Health Service.
Table 2 Baseline characteristic comparisons between DOLORisk Dundee participants and non- participants in GoDARTS and 
GS:SFHS
GoDARTS in DOLORisk dundee GS:SFHS in DOLORisk dundee
Participants Non- participants Overall Participants Non- participants Overall
(N=1915) (N=3321) (N=5236) (N=7240) (N=12 981) (N=20 221)
Age (years)* 71 73 72 60 51 55
Gender (% male) 61 53 56 39 41 40
Ethnicity (% Caucasian) 99.4 99.7 99.6 99.4 98.8 99
SIMD (%)
  1 (most deprived) 16 23 20 9 16 13
  2 16 17 16 11 16 14
  3 18 18 18 16 16 16
  4 31 28 29 28 24 26
  5 (least deprived) 19 14 16 36 28 31
*Median values given for continuous variables.
GoDARTS, Genetics of Diabetes Audit and Research in Tayside and Scotland; GS:SFHS, Generation Scotland: Scottish Family Health Study; 
SIMD, Scottish Index of Multiple Deprivation.
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in the two groups. Participants from GS:SFHS were older 
(60 years vs 51 years, p<0.01), had a lower proportion of 
males (39% vs 41%, p<0.01) and had a higher propor-
tion of Caucasians (99.4% vs 98.8%, p<0.01), compared 
with non- participants, while participants were also less 
deprived than non- participants (SIMD quintile 1: 9% vs 
16%, p<0.01).
Follow-up Survey
Approximately 18 months after the DOLORisk Dundee 
baseline survey ended, participants from both GoDARTS 
(n=1460) and GS:SFHS (n=6657) who gave their consent 
to be contacted again, had not withdrawn in the mean-
time and were still alive, were invited to participate in 
a follow- up survey. The mortality rate of DOLORisk 
Dundee participants from GoDARTS in the time period 
between the baseline survey and the follow- up survey was 
6.1% (116/1915) and in GS:SFHS was 0.5% (38/7240). 
Living participants who provided an email address in the 
baseline survey were sent an email containing a hyperlink 
to the follow- up survey website along with personal login 
credentials. The website also included a link to the study 
PIL. Simultaneously, living participants who provided 
consent for recontact but did not provide an email address 
were invited to participate in the follow- up survey by post. 
As in the baseline survey, mailings consisted of an invi-
tation letter, questionnaire, study PIL and prepaid enve-
lope. Participants of both the online and postal follow- up 
survey were sent reminders 3 weeks after the initial 
invitations. Invitations and reminders for the follow- up 
survey were sent between February and April 2019 and 
the survey was closed to respondents in June 2019. In 
GoDARTS, the response rate for the follow- up survey was 
71.6% (1046/1460) and in GS:SFHS the response rate 
was 79.5% (5292/6657).
Table 3 describes the baseline sociodemographic char-
acteristics in participants and non- participants (loss to 
follow- up, including those who were not sent a question-
naire due to non- consent or death) of the follow- up survey. 
In GoDARTS, participants were younger (69 years vs 72 
years, p<0.01) than non- participants, while in GS:SFHS 
participants were older (61 years vs 58 years, p<0.01). 
Participants from GS:SFHS were also less deprived than 
non- participants (SIMD quintile 1: 8% vs 10%, p<0.01).
Data collection
A summary of the data collected at baseline and follow- up 
and the completion rates are provided in table 4. All 
questionnaire mailing, returns and data entry/quality 
control were handled by the Health Informatics Centre 
at the University of Dundee, which is independent of 
the DOLORisk Dundee study team. This ensured that 
personal identifying information such as home and email 
addresses remained shielded from the research team. 
Questionnaire response data were made available to the 
study team via a secure bespoke database that was setup 
specifically for the DOLORisk study as a whole. Data were 
pseudonymised through the generation of study specific 
linkage IDs, which protects participant’s identities and 
confidentiality while also ensuring that data can be linked 
across different datasets.
The questionnaire for the baseline survey follows the 
common DOLORisk ‘core’ protocol for phenotyping 
participants for NP, which was agreed on by all partici-
pating centres,11 and based on pre- existing international 
consensus on NP phenotyping.15 The items that were 
included in the questionnaire can be broadly split into 
two halves, with the first half consisting of psychosocial 
items and the second half consisting of pain phenotyping 
items.
Table 3 DOLORisk Dundee loss to follow- up by baseline characteristics in GoDARTS and GS:SFHS
GoDARTS GS:SFHS
Participants Non- participants Participants Non- participants
(N=1046) (N=869)* (N=5292) (N=1948)*
Age (years)† 69 72 61 58
Gender (% male) 62 59 39 39
Ethnicity (% Caucasian) 99.3 99.4 99.5 99.1
SIMD (%)
  1 (most deprived) 14 18 8 10
  2 16 15 11 12
  3 19 18 16 15
  4 31 32 27 30
  5 (least deprived) 21 17 38 33
*Non- participant sample size includes those who were not sent a follow- up questionnaire (due to non- consent or death).
†Median values given for continuous variables.
GoDARTS, Genetics of Diabetes Audit and Research in Tayside and Scotland; GS:SFHS, Generation Scotland: Scottish Family Health Study; 
SIMD, Scottish Index of Multiple Deprivation.
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Table 4 Summary of the data collected for the DOLORisk Dundee baseline and follow- up surveys










Health- related quality of life EQ- 5D- 5L 1 90.3 95.1
Health- related quality of life EQ- VAS 2 95.7 97.4
Depression PROMIS SF4a 3a- d 85.8 95.1
Anxiety 3e- f 85.2 95.3
Sleep disturbance 4 79.8 90.6
Before the age of 18, have you ever experienced 
severe traumatic events?
NA 5 91.9 97.1
Before the age of 18, have you ever stayed in 
hospital for a long period?
NA 6 87.3 94.8
Extraversion TIPI 7a+f 86.1 95.6
Agreeableness 7b+g 87.4 96.1
Conscientiousness 7c+h 86.9 96.0
Emotional stability 7d+i 87.7 96.5
Open to new experiences 7e+j 86.9 96.2
Mouth ulcers NA 8a 91.3 96.8
Painful gums NA 8b 89.3 96.2
Bleeding gums NA 8c 89.0 96.5
Loose teeth NA 8d 87.3 95.7
Toothache NA 8e 88.4 95.9
Dentures NA 9 87.5 93.4
Ever regularly smoked tobacco? NA 10 95.7 99.7
If yes, age when started‡ NA 11 98.9 99.5
If yes, age when stopped or still smoking‡ NA 12 95.6 97.9
If yes, average no of cigars, cigarettes or grams 
of tobacco smoked in a week?‡
NA 13 92.3 96.6
How often do you currently drink alcohol? NA 14 95.6 99.6
On average how many pints of beer, 125 mL 
glasses of wine or 25 mL shots of spirit do you 
drink per week?§
NA 15 71.8 87.3
Pain Catastrophising PCS 16 86.7 96.2
Diabetic Peripheral Neuropathy MNSI 17–29/NA† 82.8 NA
Currently troubled by pain or discomfort? NA 30/17 95.6 99.0
Currently taking pain medication? NA 31/18 95.5 98.7
Pain duration¶ NA 32/19 97.0 97.8
Location of any pain¶ NA 33a/20a 94.4 96.2
Location of worst pain¶ NA 33b/20b 60.0 73.4
Pain cause¶ NA 36/23 63.4 72.7
Neuropathic pain¶ DN4 34-35/21-22 68.6 81.4
S- LANSS 38-44/25-31 77.2 92.5
24 hour average pain severity¶ BPI 37/24 95.3 95.9
Pain severity¶ CPG 45-51/32-38 88.7 96.3
Consent for follow- up NA 52/39 84.6 95.7
Continued
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For the psychosocial items, which were completed by all 
participants, validated questionnaires were used to assess 
health- related quality of life (EuroQoL- five dimensions 
five levels and Visual Analogue Scale),16 depression,17 
anxiety,17 sleep disturbance (all PROMIS SF- 4a),18 person-
ality dimensions (Ten Item Personality Inventory)19 and 
pain catastrophising (pain catastrophising scale; PCS).20 
A summary of the results from respondents of these 
psychosocial items are given in table 5, dichotomised by 
cohort. When compared with GS:SFHS, GoDARTS had 
a higher mean score in all of the psychological aspects 
(where a higher score denotes more of the concept being 
measured), including depression, anxiety, sleep distur-
bance and pain catastrophising, as well as having a lower 
mean score in the five personality traits (extraversion, 
agreeableness, conscientiousness, emotional stability and 
open to new experiences) and health- related quality of 
life.
Other factors such as adverse childhood experiences 
(ACEs), dental complications, and smoking and alcohol 
history were assessed by self- report items that were specif-
ically designed for DOLORisk.
For the phenotyping items, participants initially 
answered two screening questions, on the presence 
of current pain (‘Are you currently troubled by pain 
or discomfort, either all the time or on and off?’) and 
medication intake (‘Are you currently taking medica-
tions specifically to treat pain or discomfort?’). The first 










Health- related quality of life EQ- 5D- 5L 1 96.9 98.9
Health- related quality of life EQ- 5D- VAS 2 97.3 99.1
Depression PROMIS SF4a 3a- d 90.2 96.2
Anxiety 3e- h 89.3 96.0
Sleep disturbance 4 80.5 91.6
Pain Catastrophising PCS 5 89.4 95.6
Diabetic Peripheral Neuropathy MNSI 6–18/NA† 86.7 NA
Currently troubled by pain or discomfort?** NA 19/6 99.3 99.8
Currently taking pain medication?** NA 20/7 99.2 99.8
Pain duration†† NA 21/8 97.9 98.1
Location of any pain†† NA 22a/9a 94.7 98.6









Pain cause†† NA 25/12 68.4 85.8
Pain severity†† CPG 33-39/20-26 91.3 96.4
Do you or your doctor think that this pain is caused by any of the following? (please tick one box only).
(1) A surgical operation more than 3 months ago (2) Back problems such as a slipped disc, back surgery or sciatica (3) Bowel or other 
abdominal or pelvic problems (4) Diabetes (5) Arthritis, rheumatism, or another joint problem (6) Cancer orcancer treatment, such as 
chemotherapy (7) Any type of neuralgia, neuropathy or nerve damage (including spinal cord injury) (8) Shingles (9) Multiple sclerosis 
(10) Muscle problems, such as spasms, strains, tension or tendonitis (11) Leg ulcers (12) Loss of a limb (13) Stroke (14) Other cause/
unknown (please specify)
In the past 3 months; a) which of these pains have you had, b) which one of these pains bothered you the most?.
(1) Back pain (2) Neck or shoulder pain (3) Facial or dental pain (4) Headache (5) Stomach ache or abdominal pain (6) Pain in your arms 
(7) Pain in your hands (8) Chest pain (9) Pain in your hips (10) Pain in your legs or knees (11) Pain in your feet (12) Pain throughout your 
body (widespread pain) (13) Other pain (please specify).
*A characteristic is only considered complete if all questions that make up the characteristic are non- missing.
†Item only present in GoDARTS survey.
‡Item only answered if response to question 10 is “yes” (GoDARTS=1029/GS:SFHS=2792).
§Item only answered if response to question 14 is not “never” (GoDARTS=1300/GS:SFHS=6432).
¶Item only answered if response to either question 30/17 or 31/18 is ‘yes’ (GoDARTS=1276/GS:SFHS=4524).
**These items required a response before the online questionnaire could be submitted.
††Item only answered if response to either question 19/6 or 20/7 is "yes" (GoDARTS=702/GS:SFHS=3319)
.BPI, Brief Pain Inventory; CPG, Chronic Pain Grade; DN4, Douleur Neuropathique en 4 Questions; EQ- 5D- 5L, EuroQoL- five dimensions- 
five levels; EQ- VAS, EuroQoL- Visual Analogue Scale; GoDARTS, Genetics of Diabetes Audit and Research in Tayside and Scotland; 
GS:SFHS, Generation Scotland: Scottish Family Health Study; MNSI, Michigan Neuropathy Screening Instrument; NA, not applicable; 
PCS, Pain Catastrophising Scale; PROMIS, Patient- Reported Outcomes Measurement Information System; SF4a, short form four 
answers; S- LANSS, self- completed Leeds Assessment of Neuropathic Symptoms and Signs; TIPI, Ten Item Personality Inventory.;
Table 4 Continued
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of these questions is validated to identify cases and is the 
same as used in the original GS:SFHS cohort recruit-
ment.21 The second question was added to allow inclu-
sion of anyone whose pain was temporarily relieved by 
analgesics at the time of completing the questionnaire 
and may therefore answer ‘no’ to the preceding question. 
This has been used previously in a collaborative GWAS 
between GS:SFHS and 23andMe.22 A positive response to 
either, or both of these questions meant participants were 
invited to complete further items on pain characterisa-
tion. Those who responded negatively to both questions 
were instructed to miss out the pain characterisation ques-
tions and to immediately complete the follow- up survey 
consent section. Pain phenotyping items included the 
seven self- report items from the ‘Douleur Neuropathique 
en 4 Questions’ (DN4)23 and the seven self- report items 
of the ‘Leeds Assessment of Neuropathic Symptoms and 
Signs’ (S- LANSS).24 Both questionnaires are screening 
tools for NP and have been validated for use in popula-
tions with NP. Both screening tools have also been vali-
dated as self- report items and are therefore suitable for 
use in a postal/online survey setting. The DN4 showed 
78% sensitivity and 81% specificity, while the S- LANSS 
had 74% sensitivity and 76% specificity when compared 
with clinical examination.23 24 When compared with 
GS:SFHS, GoDARTS had a higher mean score in both the 
Table 5 Results from respondents in GoDARTS and GS:SFHS completing the pain and pain interference items
Study N* Mean SD Median IQR Theoretical range
GoDARTS EQ- 5D- 5L 1710 0.67 0.276 0.735 0.282 −1.594
PROMIS SF- 4a
Depression 1644 49.7 9.3 49 16.3 41.0–79.4
Anxiety 1632 48.7 9.4 48 15.5 40.3–81.6
Sleep Disturbance 1528 50.7 9.2 50.5 12.3 32.0–73.3
TIPI
Extraversion 1649 4 1.4 4 2 1.0–7.0
Agreeableness 1673 5.1 1.2 5 2 1.0–7.0
Conscientiousness 1665 5.4 1.3 5.5 2 1.0–7.0
Emotional stability 1679 4.9 1.5 5 2.5 1.0–7.0
Open to new experiences 1664 4.6 1.3 4.5 1.5 1.0–7.0
PCS 1661 10.2 11.8 6 14 0–52
MNSI 1586 2.6 2.5 2 4 0–13
DN4 875 2.2 2.1 2 4 0–7
S- LANSS 985 7.2 7.2 5 13 0–24
GS:SFHS EQ- 5D- 5L 6888 0.823 0.184 0.837 0.25 −1.594
PROMIS SF- 4a
Depression 6888 47.4 7.9 41 12.9 41.0–79.4
Anxiety 6899 47.9 8.5 48 13.4 40.3–81.6
Sleep Disturbance 6563 48.4 8.4 48.4 10.5 32.0–73.3
TIPI
Extraversion 6922 4.2 1.5 4 2.5 1.0–7.0
Agreeableness 6959 5.4 1.1 5.5 2 1.0–7.0
Conscientiousness 6950 5.8 1.1 6 2 1.0–7.0
Emotional stability 6983 5.1 1.5 5.5 2.5 1.0–7.0
Open to new experiences 6963 4.9 1.2 5 2 1.0–7.0
PCS 6966 6.8 8.3 4 9 0–52
DN4 3681 1.2 1.6 1 2 0–7
S- LANSS 4138 4.9 5.9 3 8 0–24
*Sample size only includes participants with non- missing responses for all questions that make up the item.
DN4, Douleur Neuropathique en 4 Questions; EQ- 5D- 5L, EuroQoL- five dimensions- five levels; GoDARTS, Genetics of Diabetes Audit and 
Research in Tayside Scotland; GS- SFHS, Generation Scotland: Scottish Family Health Study; IQR, interquartile range; MNSI, Michigan 
Neuropathy Screening Instrument; PCS, Pain Catastrophising Scale; PROMIS SF4a, Patient- Reported Outcomes Measurement Information 
System short form four answers; SD, standard deviation; S- LANSS, self- completed Leeds Assessment of Neuropathic Symptoms and Signs; 
TIPI, 10- Item Personality Inventory.
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DN4 and S- LANSS, potentially reflecting the older age of 
GoDARTS and the diabetic nature of the cohort (table 5). 
The Chronic Pain Grade was used to assess pain severity 
and disability.25 26 In addition to these screening tools, 
the Michigan Neuropathy Screening Instrument (MNSI) 
(minus two questions that do not contribute to the scoring 
algorithm) was used to assess peripheral neuropathy in 
the diabetes specific GoDARTS cohort only.27 Additional 
customised items assessed pain duration, pain location 
(by way of a checklist) and self- reported cause of pain 
(from a list of common pain aetiologies).
The follow- up survey used a truncated, but otherwise 
identical version of the baseline survey, with the items 
concerning ACEs, dental complications, personality 
dimensions, smoking and alcohol history being excluded.
In addition to the data collected through the two 
surveys, DOLORisk Dundee has access to routinely 
collected longitudinal NHS health data, available through 
both GoDARTS and GS:SFHS by way of electronic record 
linkage (table 6). This is made possible by the Commu-
nity Health Index number, which is a unique number 
assigned to each individual on first registration with NHS 
Scotland. Examples of data available through electronic 
record linkage are comorbidity, mortality and community 
dispensed prescribing. The study also has access to pre- 
existing data collected as part of GoDARTS or GS:SFHS, 
including genome- wide genotyping data.
Patient and public involvement
No patients or members of the public were directly 
involved in the design, conduct or reporting of this study. 
However, patient and public involvement was a major 
component in the establishment of GS:SFHS, including 
protocol development and principles of participation and 
data access.28 The results of the DOLORisk Dundee study 
will be disseminated to the wider patient community.
Findings to date
As the follow- up stage of this study has only recently been 
completed, no papers have yet been published using 
the DOLORisk Dundee data. However, table 1 gives the 
descriptive characteristics for participants in the base-
line survey and allows comparison of participants from 
GoDARTS and GS:SFHS. Participants from GoDARTS 
are older compared with participants from GS:SFHS (71 
years vs 60 years), have a higher proportion of males (61% 
vs 39%) and are more socially deprived (SIMD 1; 16% vs 
9%). Because GoDARTS and GS:SFHS differ in terms of 
participant recruitment, diabetes status and demographic 
characteristics, we present the two cohorts separately. In 
further research we intend to use them as discovery or vali-
dation sets.
The DOLORisk Dundee cohort will enable research into 
the identification of factors that predict NP onset, presence, 
progression, severity and remission, as well as allowing 
estimation of the prevalence (at baseline) and 18- month 
incidence. Using the pain data derived from the baseline 
questionnaires, we have found that the proportion with 
‘possible’ chronic NP was 30.5% in GoDARTS and 14.2% 
in GS:SFHS (using the definition: pain duration ≥3 months 
and DN4 score ≥3). Table 7 shows the demographic descrip-
tive statistics of participants from GoDARTS and GS:SFHS, 
comparing those with ‘possible’ chronic NP to those with 
chronic nociceptive pain (pain duration ≥3 months and 
DN4 score <3) and those with no pain. In both cohorts, 
participants with ‘possible’ chronic NP were younger, were 
less likely to be male and were more socially deprived than 
those in the other two groups.
In addition to the descriptive characteristics of 
DOLORisk Dundee, a genome- wide association study 
meta- analysis has been conducted using the aforemen-
tioned NP phenotyping data (combined with the UK 
Biobank cohort using a prescription–based phenotype). 
Similar genetic studies have been conducted for NP using 
a prescription- based phenotype in GoDARTS.29 30 Sepa-
rately, environmental risk models have been developed, 
incorporating demographic, clinical and biochemical 
predictors available through pre- existing records (table 6) 
and psychological and lifestyle data collected through the 
baseline survey. Both genetic and environmental predic-
tors have been identified in previous studies of NP.31 This 
will use similar methodologies employed in low back and 
postsurgical pain.32 33 The results of these analyses will be 
submitted for publication in the near future. Eventually 
the environmental and genetic analyses will be combined 
through the use of polygenic and environment risk scores 
to produce a joint genetic and environmental model that 
will enable better understanding of the relative contribu-
tions of genetic and environmental factors to the variation 
in NP onset and progression. Polygenic risk scores have 
already been explored to good effect in type 2 diabetes.34
Table 6 Examples of data available through pre- existing 
collections or NHS record linkage as part of GoDARTS or 
GS:SFHS
Group Examples
Demographics Age, gender, ethnicity, SIMD
Anthropometrics Height, weight, waist
Clinical Blood pressure, resting pulse
Lifestyle Smoking, alcohol 
consumption, physical activity
Scottish Morbidity Records Primary and secondary 
diagnoses
General Registrar’s Office Mortality data
Biochemistry Glucose, cholesterol, HDL
Prescribing Analgesics
Genetics Genome- wide genotyping
GoDARTS, Genetics of Diabetes Audit and Research in Tayside 
Scotland; GS:SFHS, Generation Scotland: Scottish Family Health 
Study; HDL, high- density lipoprotein; NHS, National Health 
Service; SIMD, Scottish Index of Multiple Deprivation.
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Strength and limitations
The main strength of DOLORisk Dundee lies in the size 
of the cohort, both in terms of the number of partici-
pants who responded to the questionnaire surveys (and 
provided pain data) as well as the amount of phenotypic 
data (both genetic and non- genetic) that are available 
for analyses. This makes DOLORisk Dundee one of the 
largest studies of NP to date, with statistical power to 
conduct detailed epidemiological and genetic epidemi-
ological research and the capability of being augmented 
by other cohorts within the DOLORisk consortium. 
The ability to easily combine different cohorts within 
DOLORisk is derived from the use of the ‘core’ protocol, 
which is being used by all participating centres, and this 
will extend to other cohorts that are based on the same 
phenotyping consensus.15 Furthermore, the availability of 
follow- up data on chronic pain at three time points and 
on NP at two time points allows longitudinal analysis to 
be conducted. The results of this study will enable valida-
tion in much larger cohorts and will help develop further 
areas of research in NP. One such cohort that this could 
apply to is UK Biobank, which has been rephenotyped for 
chronic pain, including NP, using a completely consistent 
phenotyping approach. Responses have been received 
from >165 000 participants in UK Biobank; these have 
not yet been analysed but will potentially include ~12 000 
with NP, assuming a prevalence of 7%.3 This would make 
UK Biobank ideal for replication studies and would easily 
overcome issues of the ‘Winner’s Curse’, where the effect 
sizes of initial studies tend to be overestimated.9
This study has some limitations. While the response rate 
for most of the individual items was good, the response rate 
to some, including those for ‘cause of pain’ and ‘location 
of worst pain’, were lower (table 4). This means that the 
study has reduced power to investigate specific locations 
and aetiologies of NP, including painful diabetic neurop-
athy, postherpetic neuralgia and trigeminal neuralgia. 
While we attempted to obtain a broad array of common 
NP aetiologies, it was not possible to capture detailed 
clinical information on neurological and sensory pheno-
types, through the medium of a self- complete question-
naire. However, the use of GoDARTS as a diabetic cohort 
will strengthen analysis relating to diabetic neuropathy, 
particularly with the use of the MNSI as a screening tool.
In retrospect, the presentation of the pain location 
questions (having a two column checklist of body loca-
tions side- by- side, with the first column for ‘any pain’ and 
the second column for ‘worst pain’) may have confused 
participants into ignoring the second question. A possible 
future solution could be to have them appearing consec-
utively rather than concurrently. Alternatively, the low 
response rate to pain that ‘bothers you the most’ could 
indicate that the question is difficult to answer.
Second, while the participants were asked about 
whether they were currently taking medications to treat 
pain, they were not asked about other forms of pain 










(N=482)* (N=461)* (N=560)† (N=932)* (N=2484)* (N=2642)†
Age (years)‡ 69.5 71§ 71§ 59 61.0§ 58.0§
Gender (% 
male)
54 58 69§ 33 38§ 42§
Ethnicity (% 
Caucasian)
99.4 99.3 99.3 99.6 99.5 99.2
SIMD (%)
  1 (most 
deprived)
22 14§ 11§ 16 7§ 6§
  2 15 15 14 16 11 9
  3 17 18 16 15 17 16
  4 29 30 35 26 29 28
  5 (least 
deprived)
17 22 24 26 37 40
Neuropathic pain and Non- neuropathic pain determined by scores greater and less than 3/7 on DN4, respectively.
No pain defined as a negative response to both chronic pain identification questions.
*Neuropathic pain and non- neuropathic pain determined by scores greater and less than 3/7 on DN4 respectively.
†No pain defined as a negative response to both chronic pain identification questions.
‡Median values given for continuous variables.
§P<0.05 (compared with neuropathic pain)
DN4, Douleur Neuropathique en 4 Questions; GoDARTS, Genetics of Diabetes Audit and Research in Tayside Scotland; GS:SFHS, Generation 
Scotland: Scottish Family Health Study; SIMD, Scottish Index of Multiple Deprivation.
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treatment, such as neuromodulation therapy. These are 
important aspects when assessing pain outcomes and will 
be considered in future surveys.
Third, the survey uses self- report, which could be 
subject to recall or reporting bias. Fourth, participants 
from DOLORisk Dundee are likely those who are particu-
larly engaged in this study, or medical research in general. 
In addition to this, participants of the baseline survey in 
GoDARTS were younger, were more likely to be male 
and to be less socially deprived than non- participants. 
Participants from GS:SFHS were older, were more likely 
to be females and Caucasians, in addition to being less 
socially deprived than non- participants. This suggests that 
DOLORisk Dundee may under represent certain sociode-
mographic categories and so should not be used to esti-
mate disease prevalence.
COLLABORATION
Collaborations with researchers interested in chronic 
(neuropathic) pain are encouraged. More information 
can be found on the DOLORisk website (http:// dolorisk. 
eu/). An access committee will be set up beyond the 
current funding period to review data access and collabo-
ration requests. Details will be made available on the study 
website once the access procedures have been decided.
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